Granahan Investment Management LLC Sells 106,957 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

Granahan Investment Management LLC reduced its stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 33.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 209,256 shares of the company’s stock after selling 106,957 shares during the quarter. Granahan Investment Management LLC’s holdings in Kiniksa Pharmaceuticals International were worth $10,076,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Mark Sheptoff Financial Planning LLC increased its stake in Kiniksa Pharmaceuticals International by 1.6% in the 4th quarter. Mark Sheptoff Financial Planning LLC now owns 16,350 shares of the company’s stock worth $674,000 after buying an additional 250 shares during the period. Mariner LLC lifted its holdings in Kiniksa Pharmaceuticals International by 2.0% during the 4th quarter. Mariner LLC now owns 13,519 shares of the company’s stock valued at $558,000 after buying an additional 266 shares in the last quarter. First Trust Advisors LP boosted its position in Kiniksa Pharmaceuticals International by 3.1% in the 1st quarter. First Trust Advisors LP now owns 9,876 shares of the company’s stock valued at $476,000 after buying an additional 293 shares during the period. Virtus Investment Advisers LLC boosted its position in Kiniksa Pharmaceuticals International by 2.5% in the 4th quarter. Virtus Investment Advisers LLC now owns 16,432 shares of the company’s stock valued at $678,000 after buying an additional 406 shares during the period. Finally, Mercer Global Advisors Inc. ADV grew its stake in Kiniksa Pharmaceuticals International by 7.1% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company’s stock worth $317,000 after acquiring an additional 508 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals International Trading Down 0.3%

Shares of NASDAQ:KNSA opened at $62.84 on Friday. Kiniksa Pharmaceuticals International, plc has a 12-month low of $26.27 and a 12-month high of $67.53. The business’s fifty day simple moving average is $56.87 and its 200-day simple moving average is $49.97. The company has a market capitalization of $4.83 billion, a PE ratio of 69.82 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.18 by $0.09. The firm had revenue of $214.27 million during the quarter, compared to analyst estimates of $206.11 million. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.11 EPS. Research analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.25 EPS for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, Director Barry D. Quart sold 13,099 shares of the business’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $50.10, for a total value of $656,259.90. Following the completion of the transaction, the director directly owned 12,546 shares in the company, valued at approximately $628,554.60. The trade was a 51.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 483,654 shares of the stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $51.86, for a total transaction of $25,082,296.44. Following the sale, the chief executive officer directly owned 431,904 shares of the company’s stock, valued at approximately $22,398,541.44. The trade was a 52.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 628,427 shares of company stock worth $32,833,228 over the last quarter. Insiders own 51.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on KNSA. The Goldman Sachs Group raised their target price on shares of Kiniksa Pharmaceuticals International from $60.00 to $75.00 and gave the stock a “buy” rating in a research report on Thursday. Wells Fargo & Company boosted their price target on Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Jefferies Financial Group increased their price objective on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. Zacks Research upgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Wednesday, June 17th. Finally, Weiss Ratings lowered Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, June 23rd. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Kiniksa Pharmaceuticals International presently has a consensus rating of “Buy” and an average price target of $68.00.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.